[118H7970]

		(Original Signature of Member)
119TH CONGRESS 1ST SESSION	H.R.	

To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information.

IN THE HOUSE OF REPRESENTATIVES

Ms. Williams of Georgia introduced the following bill; which was referred to the Committee on _____

A BILL

To require direct-to-consumer advertisements for prescription drugs and biological products to include truthful and not misleading pricing information.

- 1 Be it enacted by the Senate and House of Representa-
- 2 tives of the United States of America in Congress assembled,
- 3 SECTION 1. SHORT TITLE.
- 4 This Act may be cited as the "Plain Prescription
- 5 Prices Act".

1	SEC. 2. REGULATING ADVERTISEMENTS FOR PRESCRIP-
2	TION DRUG AND BIOLOGICAL PRODUCT
3	PRICES.
4	(a) In General.—Not later than one year after the
5	date of the enactment of this Act, the Secretary of Health
6	and Human Services, acting through the Administrator of
7	the Centers for Medicare & Medicaid Services (referred to
8	in this section as the "Administrator"), shall promulgate
9	regulations requiring each direct-to-consumer advertise-
10	ment on television (including broadcast, cable, streaming,
11	and satellite television) for a prescription drug or biologi-
12	cal product for which payment is available under title
13	XVIII or XIX of the Social Security Act to include a tex-
14	tual statement, which shall be truthful and not misleading,
15	indicating the list price, as determined on the first day
16	of the quarter during which the advertisement is being
17	aired or otherwise broadcast, for a typical 30-day regimen
18	or typical course of treatment (whichever is most appro-
19	priate).
20	(b) Determinations.—In promulgating regulations
21	under subsection (a), the Administrator shall determine—
22	(1) whether such regulations should apply with
23	respect to additional forms of advertising;
24	(2) the manner and format of textual state-
25	ments described in such subsection;
26	(3) appropriate enforcement mechanisms; and

- 1 (4) whether such textual statements should in-
- 2 clude any other price information, as appropriate.